AlTi Global Inc. Buys Shares of 387,567 Royalty Pharma plc (NASDAQ:RPRX)

AlTi Global Inc. bought a new position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 387,567 shares of the biopharmaceutical company's stock, valued at approximately $9,887,000. AlTi Global Inc. owned approximately 0.07% of Royalty Pharma at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Caisse DE Depot ET Placement DU Quebec purchased a new stake in Royalty Pharma in the 4th quarter worth $18,183,000. Regal Partners Ltd boosted its position in Royalty Pharma by 21.9% during the 4th quarter. Regal Partners Ltd now owns 1,435,956 shares of the biopharmaceutical company's stock valued at $36,631,000 after acquiring an additional 258,355 shares in the last quarter. PDT Partners LLC lifted its position in Royalty Pharma by 124.8% during the fourth quarter. PDT Partners LLC now owns 69,533 shares of the biopharmaceutical company's stock valued at $1,774,000 after acquiring an additional 38,599 shares during the last quarter. Schonfeld Strategic Advisors LLC increased its stake in Royalty Pharma by 77.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 79,142 shares of the biopharmaceutical company's stock valued at $2,019,000 after purchasing an additional 34,537 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in Royalty Pharma by 187.0% during the 4th quarter. AQR Capital Management LLC now owns 1,903,676 shares of the biopharmaceutical company's stock worth $48,563,000 after buying an additional 1,240,384 shares during the last quarter. Institutional investors own 54.35% of the company's stock.

Royalty Pharma Trading Up 1.7 %

RPRX traded up $0.56 during trading on Thursday, hitting $33.31. The company's stock had a trading volume of 4,107,015 shares, compared to its average volume of 3,287,212. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The firm's 50 day moving average price is $32.41 and its 200-day moving average price is $29.69. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock has a market cap of $19.20 billion, a PE ratio of 22.97, a PEG ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a $0.22 dividend. The ex-dividend date is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a yield of 2.64%. Royalty Pharma's dividend payout ratio (DPR) is 60.69%.

Wall Street Analysts Forecast Growth

Separately, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Royalty Pharma currently has a consensus rating of "Buy" and a consensus price target of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.